Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

January 12, 2014 12 January, 2014

Sernova to Present Company and Clinical Update at Biotech Showcase™ Healthcare Conference in San Francisco

LONDON, ONTARIO--(Marketwire – Jan. 13, 2014) - Sernova Corp (TSX-V: SVA), today announced that Dr. Philip Toleikis, Ph.D., the company’s Chief Executive Officer will present an update on the company’s business strategy and clinical study at the Biotech Showcase(TM) healthcare conference in San Francisco, CA. This important conference brings together global industry leaders, emerging companies and members of the investment community. Sernova is currently conducting a Phase I/II clinical trial of its Cell Pouch(TM) at the University of Alberta in patients with Type 1 diabetes who are receiving an islet transplant with Dr. James Shapiro as principal investigator.

Details of Sernova Corp’s presentation are as follows: Event: Biotech Showcase(TM) 2014 Conference Date: January 14, 2014 Time: 4:30 P.M. PST Location: Parc 55 Wyndham SF Union Sq. Hotel; 3(rd) Floor Track D Powell

“We are presenting Sernova’s strategic approach and product development advancements during the industry’s largest conglomerate of annual healthcare investor conferences and arguably the most important healthcare investment symposia in the industry,” remarked Dr. Philip Toleikis, President and CEO.

“With Sernova anticipating the release of Phase I/II interim clinical efficacy data in 2014, as well as advancements in our other programs and collaborations, this is an excellent opportunity to highlight the company’s progress and future direction,” added Dr. Toleikis.

About the Biotech Showcase(TM) (Innovation –Opportunity – Collaboration)

Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry’s largest annual healthcare investor conferences. Now in its sixth year, Biotech Showcase is expected to attract upwards of 1,500 attendees.

About Sernova

Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including haemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova’s proprietary technology, Sertolin(TM).

About the Cell Pouch(TM)

The Cell Pouch(TM) is a proprietary scalable biocompatible medical device, contract manufactured (ISO13485) to meet international regulatory standards. It is inserted under the skin, and forms an ideal environment, rich in microvessels and tissue matrix for the placement and function of therapeutic cells. The Cell Pouch(TM) is currently being evaluated in clinical trials at the University of Alberta with Dr. James Shapiro as principal investigator in patients with Type 1 diabetes receiving an islet transplant.

About Sertolin(TM)

Sertoli cells when co-localized with donor therapeutic cells release protective factors that can provide a non-toxic, immune-protected environment that may reduce or eliminate the need for daily anti-rejection drugs that currently must be used by patients with transplanted tissues and organs. Sernova is currently conducting preclinical studies to optimize sertoli cells and islets within the Cell Pouch(TM) through a NRC-IRAP contribution agreement provided by the Government of Canada.

About Clinical Islet Transplantation Program

Please view www.islet@ca for more information on the Clinical Islet Transplantation Program at the University of Alberta. For further information contact:

Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939

Ray Matthews and Associates Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6 604.818.7778

Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova’s management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.